Search Results

There are 122884 results for: content related to: Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain

  1. In Silico Predictions and In Vivo Results of Drug–Drug Interactions by Ketoconazole and Verapamil on AZD1305, a Combined Ion Channel Blocker and a Sensitive CYP3A4 Substrate

    Clinical Pharmacology in Drug Development

    Volume 5, Issue 5, September/October 2016, Pages: 364–373, Susanne Johansson, Boel Löfberg, Maria Aunes, Helen Lunde, Lars Frison, Nils Edvardsson and Marie Cullberg

    Version of Record online : 23 MAR 2016, DOI: 10.1002/cpdd.250

  2. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 11, November 2014, Pages: 1096–1101, A. J. Krentz, L. Morrow, M. Petersson, E. Norjavaara and M. Hompesch

    Version of Record online : 3 JUL 2014, DOI: 10.1111/dom.12323

  3. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 8, August 2013, Pages: 750–759, J. P. H. Wilding, M. Leonsson-Zachrisson, C. Wessman and E. Johnsson

    Version of Record online : 24 MAR 2013, DOI: 10.1111/dom.12088

  4. Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 12, December 2012, Pages: 1114–1122, L. A. Morrow, M. Leonsson-Zachrisson, H. Ericsson, M. Wollbratt, M. Knutsson, M. Hompesch and E. Norjavaara

    Version of Record online : 31 JUL 2012, DOI: 10.1111/j.1463-1326.2012.01661.x

  5. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 10, October 2013, Pages: 923–930, A. Kiyosue, N. Hayashi, H. Komori, M. Leonsson-Zachrisson and E. Johnsson

    Version of Record online : 22 APR 2013, DOI: 10.1111/dom.12100

  6. An S-warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator

    British Journal of Clinical Pharmacology

    Volume 83, Issue 2, February 2017, Pages: 381–392, Ken Grime, Rikard Pehrson, Pär Nordell, Michael Gillen, Wolfgang Kühn, Timothy Mant, Marie Brännström, Petter Svanberg, Barry Jones and Clive Brealey

    Version of Record online : 13 OCT 2016, DOI: 10.1111/bcp.13102

  7. You have free access to this content
    Biochemical and pharmacological characterization of AZD1981, an orally available selective DP2 antagonist in clinical development for asthma

    British Journal of Pharmacology

    Volume 168, Issue 7, April 2013, Pages: 1626–1638, JA Schmidt, FM Bell, E Akam, C Marshall, IA Dainty, A Heinemann, IG Dougall, RV Bonnert and CA Sargent

    Version of Record online : 12 MAR 2013, DOI: 10.1111/bph.12053

  8. Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors

    Veterinary and Comparative Oncology

    Volume 13, Issue 1, March 2015, Pages: 48–59, C. M. Cannon, J. Pozniak, M. C. Scott, D. Ito, B. H. Gorden, A. J. Graef and J. F. Modiano

    Version of Record online : 15 FEB 2013, DOI: 10.1111/vco.12018

  9. Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia

    Clinical and Experimental Pharmacology and Physiology

    Volume 40, Issue 3, March 2013, Pages: 212–218, Jarkko Kalliomäki, Peter Annas, Karin Huizar, Cyril Clarke, Annika Zettergren, Rolf Karlsten and Märta Segerdahl

    Version of Record online : 26 FEB 2013, DOI: 10.1111/1440-1681.12051

  10. You have free access to this content
    A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma

    British Journal of Haematology

    Volume 170, Issue 6, September 2015, Pages: 886–890, Graham P. Collins, Toby A. Eyre, Kim M. Linton, John Radford, Grant D. Vallance, Elizabeth Soilleux and Chris Hatton

    Version of Record online : 26 FEB 2015, DOI: 10.1111/bjh.13333

  11. Effects of a novel potent melanin-concentrating hormone receptor 1 antagonist, AZD1979, on body weight homeostasis in mice and dogs

    British Journal of Pharmacology

    Volume 173, Issue 18, September 2016, Pages: 2739–2751, Karolina Ploj, Lambertus Benthem, Dorota Kakol-Palm, Peter Gennemark, Liselotte Andersson, Mikael Bjursell, Jenny Börjesson, Lillevi Kärrberg, Marianne Månsson, Madeleine Antonsson, Anders Johansson, Suzanne Iverson, Björn Carlsson, Andrew Turnbull and Daniel Lindén

    Version of Record online : 3 AUG 2016, DOI: 10.1111/bph.13548

  12. You have free access to this content
    Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes

    British Journal of Pharmacology

    Volume 171, Issue 7, April 2014, Pages: 1642–1654, D J Baker, G P Wilkinson, A M Atkinson, H B Jones, M Coghlan, A D Charles and B Leighton

    Version of Record online : 18 MAR 2014, DOI: 10.1111/bph.12504

  13. You have free access to this content
    PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways

    British Journal of Haematology

    Volume 167, Issue 1, October 2014, Pages: 69–79, Koremu Meja, Chloe Stengel, Rob Sellar, Dennis Huszar, Barry R. Davies, Rosemary E. Gale, David C. Linch and Asim Khwaja

    Version of Record online : 30 JUN 2014, DOI: 10.1111/bjh.13013

  14. You have free access to this content
    AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans

    Journal of Neurochemistry

    Volume 125, Issue 3, May 2013, Pages: 446–456, Biljana Georgievska, Johan Sandin, James Doherty, Anette Mörtberg, Jan Neelissen, Anita Andersson, Susanne Gruber, Yvonne Nilsson, Pär Schött, Per I. Arvidsson, Sven Hellberg, Gunilla Osswald, Stefan Berg, Johanna Fälting and Ratan V. Bhat

    Version of Record online : 11 MAR 2013, DOI: 10.1111/jnc.12203

  15. [14C]-AZD1152 drug substance manufacture: challenges of an IV-infusion dosed human mass balance study in patients

    Journal of Labelled Compounds and Radiopharmaceuticals

    Volume 59, Issue 6, 30 May 2016, Pages: 250–254, Nick Bushby, Julie Bergin and John Harding

    Version of Record online : 12 MAY 2016, DOI: 10.1002/jlcr.3376

  16. You have free access to this content
    Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor

    Journal of Thrombosis and Haemostasis

    Volume 10, Issue 10, October 2012, Pages: 2127–2136, S. NYLANDER, B. KULL, J. A. BJÖRKMAN, J. C. ULVINGE, N. OAKES, B. M. EMANUELSSON, M. ANDERSSON, T. SKÄRBY, T. INGHARDT, O. FJELLSTRÖM and D. GUSTAFSSON

    Version of Record online : 1 OCT 2012, DOI: 10.1111/j.1538-7836.2012.04898.x

  17. Effect of encapsulating a pseudo-decapeptide containing arginine on PLGA: A solid-state NMR study

    Journal of Pharmaceutical Sciences

    Volume 99, Issue 6, June 2010, Pages: 2681–2696, Jean-Baptiste Guilbaud, Brian C. Clark, Elisabeth Meehan, Les Hughes, Alberto Saiani and Yaroslav Z. Khimyak

    Version of Record online : 28 JAN 2010, DOI: 10.1002/jps.22060

  18. You have free access to this content
    AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro

    Clinical Microbiology and Infection

    Volume 10, Issue 3, March 2004, Pages: 247–254, A. Wookey, P. J. Turner, J. M. Greenhalgh, M. Eastwood, J. Clarke and C. Sefton

    Version of Record online : 3 MAR 2004, DOI: 10.1111/j.1198-743X.2004.00770.x

  19. Initial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program

    Pediatric Blood & Cancer

    Volume 61, Issue 11, November 2014, Pages: 1972–1979, Peter J. Houghton, Raushan T. Kurmasheva, Dmitry Lyalin, John M. Maris, E. Anders Kolb, Richard Gorlick, C. Patrick Reynolds, Min H. Kang, Stephen T. Keir, Jianrong Wu and Malcolm A. Smith

    Version of Record online : 17 AUG 2014, DOI: 10.1002/pbc.25175

  20. You have free access to this content
    Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand

    Journal of Neurochemistry

    Volume 114, Issue 3, August 2010, Pages: 784–794, Anders Juréus, Britt-Marie Swahn, Johan Sandell, Fredrik Jeppsson, Allan E. Johnson, Peter Johnström, Jan A. M. Neelissen, Dan Sunnemark, Lars Farde and Samuel P. S. Svensson

    Version of Record online : 13 MAY 2010, DOI: 10.1111/j.1471-4159.2010.06812.x